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ABSTRACT (word count 249) 
Background. Repeated measurements of spirometry and fractional exhaled nitric oxide (FeNO) are 
recommended as part of the management of childhood asthma, but the evidence base for such 
recommendations is small.  We tested the hypothesis that reducing spirometric indices or increasing 
FeNO will predict poor future asthma outcomes.  
Methods.  A one-stage individual patient data meta-analysis used data from seven randomised 
controlled trials where FeNO was used to guide asthma treatment, and where spirometric indices 
were also measured.  Change in %FEV1 and % change in FeNO between baseline and three months 
were related to having poor asthma control and to having an asthma exacerbation between three 
and six months after baseline.   
Results. Data were available from 1112 children (mean age 12.6 years, mean %FEV1 94%). A 10% 
reduction in %FEV1 between baseline and three months was associated with 28% increased odds for 
asthma exacerbation [95% CI 3, 58] and with 21% increased odds for having poor asthma control 
[95% CI 1, 45] six months after baseline. A 50% increase in FeNO between baseline and three months 
was associated with 11% increase in odds for poor asthma control six months after baseline [95% CI 
0, 16]. Baseline FeNO and %FEV1 were not related to asthma outcomes at three months.   
Conclusions. Repeated measurements of %FEV1 which are typically within the “normal” range add to 
clinical risk assessment of future asthma outcomes in children. The role of repeated FeNO 
measurements is less certain since large changes were associated with small changes in outcome 
risk.  
Keywords: Asthma, Child, Monitoring, Nitric oxide, Spirometry 
 
  
Page 3 of 57
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL
4 
 
ABBREVIATION LIST 
BUD Budesonide 
ERS European Respiratory Society 
FeNO Fractional Exhaled Nitric Oxide 
FEF25-75 Forced Expiratory Flow at 25-75% of FVC 
FEV1 Forced Expiratory Volume in one second 
FVC Forced Vital Capacity 
GLI Global Lung Initiative 
ICS Inhaled corticosteroid 
IPD Individual Patient Data Analysis 
IQR Inter-quartile range 
LABA Long Acting Beta Agonist 
LTRA Leukotriene Receptor Antagonist 
NHANES National Health and Nutrition Examination Survey 
OR Odds ratio 
ppb Parts per billion 
RCT Randomised Controlled Trial 
SD Standard deviation 
UK United Kingdom 
USA United States of America 
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INTRODUCTION 
Asthma is a common condition affecting 1 million children in the UK
1
 and 6 million in the USA
2
.  
Guidelines recommend that objective markers of respiratory function (e.g. forced Expiratory Volume 
in one second (FEV1)) and airway inflammation (e.g. fractional exhaled nitric oxide, FeNO) may be 
used in conjunction with symptoms to guide asthma preventive treatment in children.  However 
these recommendations differ between guidelines, and none gives clinicians advice how to interpret 
changes in spirometry when values fall within the normal range, yet FEV1 (the most commonly used 
spirometric index) is usually within normal limits 
3
.   
One guideline recommends that lung function should be “monitored and recorded” only in children 
aged over 12 years
4
.  Two guidelines recommend that FEV1 may be useful for monitoring of asthma 
for children aged over five to seven years
5, 6
. A fourth guideline
7
 recommends that lung function 
should be measured three-to-six months after treatment is started and “periodically” thereafter, and 
that %FEV1 less than 60% identifies a patient at risk for future asthma exacerbations.  A fifth 
guideline
8
 recommends that lung function should be measured every one to two years (more 
frequently when symptoms are poorly controlled) and suggests that treatment might be stepped up 
if %FEV1 is below 80% or 60%.  Some guidelines suggest that a 20% drop in FEV1 relative to personal 
best identifies an individual at risk for future asthma exacerbations
5, 7
.  
Although FeNO is recommended by the US Food and Drug Administration for monitoring asthma
9
 
there is no consensus on how results should be interpreted; one international guidelines states that 
a change in FeNO of 10 parts per billion or 20% may be clinically relevant
10
.   
To understand the relationship between change in spirometry and FeNO and asthma outcomes we 
obtained individual patient data (IPD) from seven FeNO randomised controlled  trials (RCTs) where 
details of spirometry, FeNO, asthma control and the occurrence of asthma exacerbations were 
collected longitudinally 
11-17
.  Our primary hypothesis was that falling spirometric indices (with %FEV1 
as the primary index) and/or rising FeNO between randomisation and three months follow up will be 
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associated with increased risk for asthma being uncontrolled and for an asthma exacerbation 
between three and six months follow up.  The secondary hypothesis was that at baseline, low 
spirometric indices and high FeNO will be associated with increased risk for asthma being 
uncontrolled and for an asthma exacerbation between baseline and three months follow up. 
 
METHODS 
Study design   
Authors of published RCTs where measurements of FeNO was used to guide asthma treatment in 
children
18
 were invited to provide anonymised data for IPD
19
. The outcomes were asthma 
exacerbation (defined as a prescription of prednisolone during the follow-up period and derived 
using data provided by study authors) and poor asthma control (defined by per trial protocol by 
symptom score, and including FEV1 cut off values in some trials
11, 12, 16
 but not including an asthma 
exacerbation).  The supplement provides definitions of being uncontrolled.  For all RCTs, prescribing 
of oral corticosteroids for asthma exacerbations was at the discretion of the attending doctor.  The 
explanatory variables between baseline and three months follow up were absolute change and 
%change in FeNO and absolute change in percentage of predicted (%) spirometry; the analysis of 
change in % spirometry and % change in FeNO included the corresponding baseline measurement.  
The relationship between outcomes and the following explanatory variables at baseline were 
sought: FeNO and %FEV1, %FEV1/FVC, %FEF25-75 and %FVC.  Figure one shows which physiological 
measurements (and changes) were linked to later asthma outcomes in this study.  Additional 
covariates collected at baseline and included in the models were: age, gender, height, weight, 
ethnicity, trial arm, dose of inhaled corticosteroid (ICS, as daily budesonide equivalent dose, BUD), 
prescribed long acting beta agonist (LABA) or not, prescribed leukotriene receptor agonist (LTRA) or 
not, asthma control and treatment compliance. For each follow up visit, the following variables were 
collected: FeNO, FEV1, height, dose of ICS, asthma control and asthma exacerbation since the 
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previous visit.  The focus of this study was follow up at three and six months since these are typically 
used in asthma clinics; for trials where there was no three or six month assessment, the assessment 
closest to these time points was used.  In all but two studies
14, 15
, absolute spirometry data were 
available and expressed as percentage of predicted to the Global Lung Initiative standard
20
; where 
absolute data were not available, the % predicted value provided by the local team was used for 
analysis. Whilst %FEV1 was the primary spirometric index of interest, %FEV1/FVC, %FEF25-75 and %FVC 
were also considered to determine which index had the greatest precision for future outcomes.  For 
completeness, FEV1 was also expressed as a Z scores and centile (standardised to the Global Lung 
Initiative standard
20
).  Additionally, as a sensitivity analysis, %FEV1 was derived using National 
Asthma Education and Prevention Program (NHANES) III standard
21
 to determine whether any 
relationship between %FEV1 and later outcome was dependent on the standard used.   Body Mass 
Index (BMI) was derived and International Obesity Task Force weight categories created
22
. In each 
trial, FeNO was measured in accordance with the 2005 guideline
23
.  Ethical approval was obtained 
for each individual study but was not required for the IPD. 
 
Individual patient data analysis 
Demographic and baseline characteristics were obtained for each study. A one-stage IPD meta-
analysis was undertaken using the melogit command in STATA with study included as a random 
effect. All models were adjusted for the baseline variables of age, gender, LABA, LTRA, asthma 
control, ICS dose, arm of trial and where relevant baseline FeNO or baseline FEV1. A one-stage 
approach was used rather than a two-stage as some of the studies had low event counts (few 
asthma exacerbations) and adoption of one-stage in this instance is recommended by Burke et al
24
. 
Sensitivity analyses considered separately outcomes for individuals in FeNO intervention and 
standard care arms of the trials, and also excluding data from trials where %FEV1 was used to guide 
treatment decisions 
11, 12, 16
. STATA version 14 was used for analysis. 
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RESULTS 
Study subjects 
Data from seven paediatric RCT were analysed 
11-17
, data from an eighth RCT could not be obtained 
25
.  Details of population inclusion and exclusion criteria are presented in the supplement. The IPD 
included data on 1112 participants. In two studies
14, 17
 spirometry was only measured at baseline and 
at 12 months and change in %FEV1 between baseline and three months could not be calculated.  
There was a predominance of male participants (58%) and mean (standard deviation(SD)) age was 
12.6 (3.1) years, table 2.  Median values of FeNO varied between 18 and 34 parts per billion (ppb) 
with an overall median (interquartile range (IQR)) of 22ppb (12, 43). Mean %FEV1 values at baseline 
varied between 89% and 98% predicted with an overall mean (SD) of 94% (18).  Details of mean FEV1 
z scores and centile are presented in supplemental table 1. The Pearson correlation coefficient 
between FeNO and %FEV1 at baseline was -0.184 (n=1025, p <0.001) and between % change in FeNO 
(baseline to 3 months) and change in %FEV1 (baseline to 3 months) was -0.127 (n=759, p <0.001). 
Overall 7% of participants had an asthma exacerbation during the first 3 months and 12% in the 
second three months, while 27% were uncontrolled at baseline, 25% at 3 months, and 23% at six 
months, table 3.  An asthma exacerbation occurred between baseline and three months in 47 (7%) 
of the 718 participants with controlled symptoms at baseline and in 27 (12%) of 230 with 
uncontrolled symptoms at baseline.  
 
Relationship between change in spirometry and percentage change in FeNO between baseline and 
three months and outcomes between three and six months 
Between baseline and 3 months, the mean (SD) change in %FEV1 was -0.17 (10.4), the median 
absolute change in FeNO was 0.6 ppb (IQR -7.9, 12.2) and the median % change in FeNO 
(interquartile range) was 3.7% (IQR -30.4, 66.7).  A fall in % FEV1 was related to increased odds of an 
asthma exacerbation over the following three months (e.g. a reduction of 10% FEV1 between 
baseline and three months was associated with increased odds ratio (OR) for future exacerbation 
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between three and six months of 1.3 [1.0, 1.6], p=0.027) and loss of future asthma control (e.g. a 
reduction of 10% FEV1 was associated with increased odds ratio for uncontrolled asthma 1.2 [96% CI 
1.0, 1.5], p=0.046), table 4.  A reduction of 10% FVC was also associated with increased odds for a 
future exacerbation (OR 1.40 [1.04, 1.88], p=0.026), supplemental table 2.  A 50% increase in FeNO 
between baseline and three months was associated with 11% increased odds of asthma being 
uncontrolled at six months [95% 0, 16] (p=0.014) but not odds of an exacerbation between three 
and six months, table 4. When both change in %FEV1 and %change in FeNO were considered in the 
same model, the odds ratio for asthma being uncontrolled remained significant for FeNO (p=0.036) 
but not for %FEV1 (p=0.061).  Neither change in %FEV1/FVC or %FEF25-75 (supplemental table 2) nor 
absolute change in FeNO (table 4) were associated with outcomes. The associations between change 
in %FEV1 and % change in FeNO did not achieve significance when each trial arm was considered 
separately (supplemental table 3).  When the RCTs where %FEV1 was used to guide treatment were 
excluded there was an association between rising FeNO and future asthma exacerbation (p=0.029) 
but associations between change in FEV1 and outcomes were not significant, supplemental table 4.  
Among the subset of RCT where FEV1 z score and centile values could be derived, falling z scores 
were associated with increased odds for both asthma exacerbations and being uncontrolled and 
falling centile score with being uncontrolled, supplemental table 5. The results seen with change in 
% FEV1 using the Global Lung Initiative (GLI) standard were also seen when the NHANES III standard 
was used, supplemental table 6.   
 
Relationship between baseline FeNO and spirometric indices and outcomes at three months 
Percentage of predicted FEV1/FVC at baseline (but no other spirometric index) was related to the 
odds of asthma exacerbation at three months during this interval (p=0.016), table 5.  No index of 
spirometry at baseline was related to having uncontrolled asthma at three months.  FeNO at 
baseline was not related to asthma outcomes at three months (table 5).  Supplementary table 6 
demonstrates that when FEV1 was standardised to the NHANES III data, reducing %FEV1 at baseline 
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was associated with increased odds for future asthma exacerbation (p=0.033) and a trend for 
reduced odds for asthma not being controlled in future (p=0.055).  Baseline FEV1 z score or centile 
were not related to outcomes (supplemental table 7). 
 
DISCUSSION 
This study sought to understand the relationship between changes in spirometric measurements and 
FeNO and future asthma outcomes.  The first finding was that, independent of all factors which 
might influence treatment decisions, falling %FEV1 (even within the range of 80-120% commonly 
considered as “normal”) was associated with increased odds for future asthma exacerbation and 
having uncontrolled asthma.  A second finding was that an absolute change in FeNO (table 4) did not 
predict outcomes, and only a large rise in % change in FeNO was related to a small increase in the 
odds for having uncontrolled asthma in future.  We also observed that at baseline, a “one off” 
%FEV1/FVC ratio (but not %FEV1) was associated with future odds for asthma exacerbation.  
Together the results suggest that change in %FEV1 can be used as part of risk assessment for asthma 
outcomes.  The role of change in FeNO is less clear and future clinical trials could include % change in 
FeNO as part of a treatment algorithm for children with asthma. 
The individuals whose data contributed to this study were participating in RCTs, and this could mean 
that the results are not necessarily generalisable for at least two reasons.  First, participants in RCTs 
often have to fulfil specific eligibility criteria, receive more clinical contact than standard care and 
often have better outcomes such as fewer asthma exacerbations, but these differences are likely to 
weaken any association between FeNO or %FEV1 and asthma outcomes by narrowing the phenotype 
of participants and improving outcomes.  Secondly, the participants in our study had treatment 
guided by FeNO (and %FEV1 in three studies) and thus the predictive variables in our study may have 
affected the outcome (e.g. rising FeNO leading to increased ICS resulting in good asthma control).  
We justify inclusion of data from these trials because firstly FeNO and, in all but one study
14
, %FEV1 
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did not differ between trial arms and secondly, if FeNO or %FEV1 did improve asthma outcomes by 
protocol-driven treatment changes this would have weakened any association between FeNO or 
%FEV1 and asthma control or asthma exacerbations.  Our inclusion of participants in RCTs may 
therefore have weakened the associations described, and in “real life” change in %FEV1 and % 
change in FeNO may have greater precision for outcomes than indicated by our results.  
There are some limitations to our study.  First, the methodologies of the RCTs were different and in 
particular in three of the RCTs
15-17
 the intervals between assessments did not include multiples of 
three months, and this heterogeneity may have weakened the associations described, assuming that 
the relationship between FeNO and FEV1 and outcomes changes over time. Different methods were 
used to assess asthma control; again this would weaken and not strengthen the associations 
described between baseline %FEV1 or %change in FeNO and being uncontrolled in future.  A second 
limitation is that the range of %FEV1 values was relatively narrow and the incidence of asthma 
exacerbations was relatively low and this could make the relationship between physiological 
measurement and clinical outcome difficult to detect, but nonetheless we were still able to observe 
an association between %FEV1 and future asthma exacerbations.  A third limitation is that we did not 
have an objective measure of adherence and could not consider how non-adherence may have 
influenced asthma control and exacerbations, however this information is not available for most 
clinicians and thus our study reflects “real world”.  A fourth limitation is that none of the RCTs 
included an assessment of short-term variability of pulmonary function, such as peak expiratory flow 
variability or bronchodilator response, and we are not able to say how short-term variability in 
pulmonary function might be related to future asthma outcomes. 
The magnitude of the change in odds ratio for an asthma exacerbation or being uncontrolled in 
future in the context of changing %FEV1 and FeNO were relatively small, and this is partly due to our 
including RCT participants as previously discussed and partly due to the fact that the model 
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considered many other factors which might predict poor asthma outcomes, e.g. current symptom 
control, treatment level, current %FEV1.  
In our sensitivity analyses we excluded the three studies where %FEV1 was used to guide treatment 
and the results seen in the whole population were no longer significant and this is most likely 
explained by lack of power. We when split results by trial arm, and the significant associations seen 
between change in %FEV1 and %change in FeNO for the whole population were also non-significant 
and this is also most likely due to lack of power in the analysis.   
We are not aware of published studies which relate change in spirometry to future asthma 
outcomes, but there are several studies where spirometry on a single occasion has been related to 
subsequent asthma outcomes in children.  One study reported an inverse relationship between 
reduced %FEV1 and increased risk for asthma exacerbation in the next 12 months
26
.  Two further 
studies
27, 28
 (data from one
27
 contributed to the present IPD) reported that reduced FEV1/FVC ratio 
was associated with increased risk for future exacerbation.   
The 2015 European Respiratory Society (ERS) Task Force on Monitoring Asthma in Children
29
 stated 
that “the meaning of significant changes in FeNO in a longitudinal setting is still unclear and needs 
further attention, and that “the use of ‘personal best’ cut-off points in FeNO algorithms requires 
further investigation”.  Our study findings suggest that a % relatively large rise (50%) in FeNO over 
three months (independent of treatment and initial symptoms) may be a useful predictor of having 
uncontrolled asthma in future but not for asthma exacerbations. Additionally, our results suggest 
that a single FeNO value and absolute change in FeNO over time are unlikely to be clinically useful. 
In summary our results suggest that %FEV1 within the “normal” range over three month periods 
could assist with risk assessment in childhood asthma and these findings now need replicating 
elsewhere.  A fall in %FEV1 and a rise in FeNO should prompt an evaluation of medication adherence, 
inhaler technique, perception of symptoms and exposure to either allergens or viral infection. The 
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relationship between changes in FeNO measurements and asthma outcomes is less clear and 
requires further evaluation.  
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FIGURE LEGEND 
Figure one.  A diagram showing how different physiological measurements were linked to later 
asthma outcomes in the study’s analyses. The analyses used data collected at recruitment to seven 
clinical trials and at follow up assessments three and six months after recruitment.*Although % FEV1 
was the primary spirometric index, the following were also considered: %FEV1/FVC, %FEF25-75 and 
%FVC.  
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Table 1.  Details of the randomised controlled trials included in this individual patient data analysis 
 Mean age, y  
 
Intervals at follow up 
after baseline when 
FeNO was measured 
(months). Zero 
corresponds to baseline. 
Intervals at follow up after 
baseline when spirometry 
was measured (months).  
Zero corresponds to 
baseline  
Were 
absolute 
spirometry 
data 
available? 
Which 
spirometric 
indices were 
available? 
Was 
there a 
run in 
period? 
Was 
atopy an 
inclusion 
criteria?  
What measure of asthma 
control was used? 
FeNO 
arm 
Control 
arm 
Fritsch
11
 11.3 12.1 0, 1.5, 3, 4.5, 6 0, 1.5, 3, 4.5, 6 Yes FEV1, FVC Yes Yes Unvalidated symptom diary 
Peirsman
12
 10.6 10.7 0, 3, 6, 9, 12 0, 3, 6, 9, 12 Yes FEV1 No Yes First four (of seven) questions 
on CACT*† 
Petsky
13
 9.9 10.1 0, 1, 2, 3, 4, 6, 8, 10, 12 0, 1, 2, 3, 4, 6, 8, 10, 12 Yes FEV1, FEF25-75, 
FVC 
Yes No Validated symptom diary 
Pijnenburg
14
 11.9 12.6 0, 3, 6, 9, 12 0, 12 No FEV1, FEF50, 
FVC 
Yes Yes Validated symptom diary 
Pike
15
 10.5 11.4 0, 2, 4, 6, 7, 10, 12 0, 2, 4, 6, 7, 10, 12 No FEV1, FVC No No Modified validated symptom 
diary† 
Szefler
16
 14.4 14.4 0, 1.5, 3.2, 5, 7, 8.5, 10.5 0, 1.5, 3.2, 5, 7, 8.5, 10.5 Yes FEV1, FEF25-75, 
FVC 
Yes No ACT*‡ plus FEV1 
Voorend-van 
Bergen
17
 
10.3 10.2 0, 4, 8, 12 0, 12 Yes FEV1, FEF75, 
FVC 
Yes Yes ACT and C-ACT* 
 
*ACT = asthma control test, C-ACT=Childhood Asthma Control Test 
†reliever medication use and FEV1 or ¶FEV1 alone were used in the treatment algorithm for both arms of the RCT but were not used to define being 
uncontrolled in the present study 
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Table 2. Characteristic of study participants at the baseline visit in each study 
  
Fritsch
11
 Peirsman
12
 Petsky
13
 Pijnenburg
14
 Pike
15
 Szefler
16
 
Voorend-van 
Bergen
17
 
All populations 
combined 
Total number of participants 47 99 63 86 90 546 181 1112 
%(number) male 60% (28) 67% (66) 49% (31) 65% (56) 57% (51) 53% (288) 68% (123) 58% (643) 
Age mean (SD) 11.5(3.1) 10.7 (2.1) 10.0 (3.2) 12.3 (2.8) 10.9 (2.6) 14.4 (2.1) 10.2 (3.0) 12.6 (3.1) 
range 6 to 17 5 to 14 4 to 16 6 to 18 5 to 16 12 to 19 4 to 18 4 to 19 
Trial arm Standard 25 50 32 46 46 270 92 561 
FeNO 22 49 31 40 44 276 89 551 
FeNO Number of observations 46 49 61 86 90 546 179 1057 
Median (ppb) 33.9 31.3 25.6 32 25.5 20.1 18.2 21.9  
IQR (ppb) (18.6, 58.6) (14, 69) (12.2, 47.5) (16.6, 52.5) (10, 48) (11.2, 40.6) (10.2, 30.4) (11.6, 43.0) 
% predicted 
FEV1 
Number of observations 47 98 54 86 90 546 157 1078 
mean (SD) 93.5 (15.7) 91.4 (15.7) 90.7 (15.6) 97.5 (17.5) 89.2 (14.3) 90.9 (16.6) 93.8 (13.0) 93.5 (18.1) 
% predicted 
FEV1/FVC 
Number of observations 47 0 0 0 0 546 156 749 
mean (SD) 90.1 (10.6) - - - - 91.3 (9.9) 93.4 (9.4) 91.7 (9.9) 
% with positive skin prick test  
100% 100% 
38% 
(24/63) 
100% 
76%       
(68/90) 
88%  
(467/531) 
100% 
89%  
(972/1097) 
Mean Centile 
BMI (SD) 
Number of observations 47 99 58 86 89 546 181 1106 
mean (SD) 67.6 (27.0) 52.1 (30.1) 48.5 (32.4) 60.8  (27.3) 64.2 (32.2) 83.1 (23.5) 58.9 (29.9) 70.7 (29.8) 
 
Obese 
Number of observations 47 99 58 85 89 526 181 1085 
% (number) overweight 28% (13) 12% (12) 16% (9) 14% (12) 25% (22) 28% (145) 20% (36) 23% (249) 
% (number) obese 8% (4) 1% (1) 2% (1) 4% (4) 8% (7) 31% (165) 3% (5) 17% (187) 
LTRA 
treatment 
prescribed 
Number of observations 47 99 58 86 90 546 181 1107 
% (number) yes  28% (13) 60% (59) 10% (6) 0 51% (46) 15% (80) 13% (23) 
21% (227) 
LABA Number of observations 47 99 58 86 90 546 181 1107 
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treatment 
prescribed 
% (number) yes  38% (18) 32% (32) 67% (39) 38% (33) 76% (68) 66% (360) 46% (84) 
57% (634) 
Median dose of inhaled corticosteroids 
(IQR)  
400 (0, 800) 320 (200, 400) 
400 (250, 
500) 
800 (400, 
1000) 
800 (400, 
1000) 
1000 (400, 
2000) 
400 (400, 
800) 
400 (400, 
1000) 
 
Ethnic group 
Number of observations 0 84 20 0 90 526 179  889 
White  82% (69)   92% (83) 
 
89% (160) 35% (312) 
Hispanic      65% (340) 
 
38% (340) 
 Other  18% (15) 100% (20)  8% (7) 35% (186) 11% (19) 28% (247) 
Asthma 
control 
status 
Number of observations 47 65 57 77 90 528 181 1045 
Asthma controlled 49% (23) 75% (49) 72% (41) 57% (44) 68% (62) 80% (421) 67% (122) 73% (762) 
Asthma not Controlled 51% (24) 25% (16) 28% (16) 43% (33) 31% (28) 20% (107) 33% (59) 27% (283) 
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Table 3.  Frequency of outcomes between baseline and three months and between three and six months post baseline.   
 
 
 
 
 
 
 
 
 
 
  
 
Exacerbation between 
baseline and three 
months 
Exacerbation 
between three 
and six months 
Asthma not 
controlled at 
three months 
Asthma not 
controlled at 
six months 
  % (n) % (n) % (n) n (%) 
Fritsch
11
 2% (1/47) 6% (3/47) 54% (25/46) 53% (25/47) 
Peirsman
12
 4% (4/99) 0% 25% (21/83) 21% (18/86) 
Petsky
13
 5% (3/63) 8% (5/63) not available not available 
Pijnenburg
14
 9% (8/86) 8% (7/86) 40% (32/81) 40% (31/78) 
Pike
15
 17% (15/90) 30% (27/90) 26% (23/90) 32% (29/90) 
Szefler
16
 7% (35/522) 15% (78/505) 21% (111/541) 17% (86/513) 
Voorend-van Bergen
17
 7% (12/181) 7% (12/181) 21% (38/179) 20% (36/178) 
Overall 7% (78/1088) 12% (132/1071) 25% (250/1010) 23% (225/992) 
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Table 4.  Relationship between falling % FEV1 or rising %change in FeNO over a three month period and odds of having an asthma attack or uncontrolled 
asthma during the next three months.  Results are from a one stage individual patient data analysis.  All models adjusted for sex, age, treatment with long 
acting beta agonists at baseline, treatment with leukotriene receptor antagonist at baseline, asthma control at baseline, change in dose of inhaled 
corticosteroid between baseline and three months. *For change in %FEV1, “per unit” means for each percentage change (e.g. from 98% to 97% FEV1) and 
for %change in FeNO means for each percent change (e.g. from 100 to 101ppb) and absolute change in FeNO “per unit” means per part per billion change 
(e.g. from 35 to 36ppb).  †Odds ra]o for outcomes were derived from the odds ra]o per unit change, for example odds ra]o for asthma attack after a 
reduction in %FEV1 of 5 is 1.025 to the power of 5.   ‡The model also includes asthma attack between baseline and 3 months.  The change in FeNO model 
included FeNO at baseline and the change in FEV1 model included FEV1 at baseline. 
Change in 
measurement of 
respiratory 
function 
Asthma outcome Odds Ratio per 
unit change in 
FEV1 or FeNO* 
Odds Ratio per 5, 10 and 20 reduction in %FEV1† Odds Ratio per 20 and 50% 
increase in FeNO† 
Odds Ratio per 20 and 50ppb 
increase in FeNO† 
%FEV1 
reduced by 5  
%FEV1 
reduced by 10 
%FEV1 reduced 
by 20 
20% increase 
in FeNO 
50% increase 
in FeNO 
20ppb increase 
in FeNO 
50ppb 
increase in 
FeNO 
 
Change (baseline 
to 3m) in% FEV1 
≥1  asthma attack 
between three 
and six months‡ 
1.025 (1.003, 
1.047) p=0.027 
n=716 (5 trials) 
1.131 
[1.015, 1.258] 
1.280          
[1.030, 1.583] 
1.639          
[1.062, 2.506] 
  
Asthma 
uncontrolled at 
six months 
1.019 (1.000, 
1.038) p=0.046 
n=693  (4 trials) 
1.099 
[1.000, 1.205] 
1.207        
[1.000, 1.452] 
1.457        
[1.000, 2.108] 
 
% change in 
FeNO (baseline 
to 3m) 
≥1  asthma attack 
between three 
and six months‡ 
1.001 (0.999, 
1.003) p=0.228 
n=929 (7 trials) 
 1.020           
[0.980, 1.062] 
1.051         
[0.951, 1.162] 
Asthma 
uncontrolled at 
six months 
1.002 (1.000, 
1.003) p=0.014 
n=897 (6 trials) 
1.041           
[1.000, 1.062] 
1.105         
[1.00, 1.162] 
 
Absolute change 
in FeNO 
(baseline to 3m), 
ppb 
≥1  asthma attack 
between three 
and six months‡ 
1.004 (0.998, 
1.010) p=0.197 
n=929 (7 trials) 
 1.083        
[0.961, 1.220] 
1.221            
[0.905, 
1.645] 
Asthma 
uncontrolled at 
six months 
1.002 (0.997, 
1.008) p=0.407 
n=897 (6 trials) 
1.041          
[0.942, 1.173] 
1.105         
[0.861, 
1.489] 
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Table 5.  Relationship between baseline % FEV1 or baseline FeNO and odds of asthma attack or 
asthma being uncontrolled during the next three months.  Results are from a one stage individual 
patient data analysis.  All models adjusted for sex, age, treatment with long acting beta agonists at 
baseline, treatment with leukotriene receptor antagonist at baseline, asthma control at baseline and 
change in dose of inhaled corticosteroid between baseline and three months. *For %FEV1, “per unit” 
means for each percentage reduction (e.g. from 98% to 97% FEV1) and for FeNO “per unit” means 
per part per billion change (e.g. from 35 to 36ppb). 
 
Measurement of 
respiratory function 
Asthma outcome Odds Ratio per unit* reduction in 
FEV1 or rise in FeNO 
 
 
%FEV1 at baseline 
 
≥1 asthma attack between 
baseline and three months 
1.011(0.997, 1.026) p=0.118 
n=973 (7 trials) 
Asthma uncontrolled at three 
months 
0.993 (0.984, 1.001) p=0.098 
n=939 (6 trials) 
 
%FEV1/FVC at baseline 
 
≥1 asthma attack between 
baseline and three months 
1.037 (1.007, 1.067) p=0.016 
n=706 (3 trials) 
Asthma uncontrolled at three 
months 
0.993 (0.973, 1.012) p=0.451 
n=715 (3 trials) 
 
 
FeNO (ppb) at baseline 
≥1 asthma attack between 
baseline and three months 
1.001 (0.995, 1.008) p=0.682 
n=966 (7 trials) 
Asthma uncontrolled at three 
months 
1.002 (0.997, 1.007) p=0.476 
n=929 (6 trials) 
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Figure one.  A diagram showing how different physiological measurements were linked to later asthma 
outcomes in the study’s analyses. The analyses used data collected at recruitment to seven clinical trials and 
at follow up assessments three and six months after recruitment.*Although % FEV1 was the primary 
spirometric index, the following were also considered: %FEV1/FVC, %FEF25-75 and %FVC.  
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SUPPLEMENT 
 
Details of each population  
Fritsch et al
1
 undertook a study of 47 children with asthma attending a hospital asthma clinic in Vienna, Austria and collected data at baseline, 1.5, 3, 4.5 
and 6 months (see table 1). The intervention compared treatment guided by symptom and FEV1 (applying a cut off of 80% of predicted) versus symptoms, 
FEV1 and FeNO (applying a cut off of 20 parts per billion, ppb).  The data collected at baseline, three and six months were used for the IPD.  FeNO was 
measured using a NIOX chemiluminescence analyser (Aerocrine AB, Solna, Sweden). Sensitisation to inhaled allergen was an inclusion criterion and children 
treated with oral or intravenous corticosteroids within four weeks prior to the baseline visit were excluded.  Reported asthma symptoms over a four week 
period were scored as 0 (no symptoms, i.e. controlled), 1 (mild symptoms, i.e. controlled) and 2 (severe symptoms, i.e. uncontrolled).  Prescribing of oral 
corticosteroids for asthma attacks was at the discretion of the attending doctor. 
Peirsman et al
2
 recruited 99 participants with persistent asthma attending one of seven hospital asthma clinics across Belgium and collected data at 
baseline, three, six, nine and twelve months (see table 1).  The intervention compared treatment guided by symptoms plus %FEV1 (applying a cut off of 80% 
predicted) against symptoms, %FEV1 and FeNO (with a cut off of 20ppb).  FeNO was measured using the NIOX MINO device (Aerocrine AB, Solna, Sweden).  
All participants were sensitised to inhaled allergens.  Inclusion criteria included mild to severe persistent asthma and sensitised to inhaled allergen. Children 
with an asthma attack in the previous four weeks or who had received treatment with oral corticosteroids in the previous twelve weeks were ineligible.  
The first four questions of the children Asthma Control Test were used to ascertain asthma control.  Prescribing of oral corticosteroids for asthma attacks 
was at the discretion of the attending doctor. 
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Petsky et al
3
 recruited 63 children in Australia and Hong Kong and data were collected at baseline, one, two, three, four, six, eight, ten and twelve months. 
If three month data were missing, two month data were used, and if six month data were missing, the four month information was used in the IPD. The 
intervention compared asthma treatment guided by symptoms versus symptoms plus FeNO (applying a cut off of 10ppb for non-atopic children, 12ppb for 
those with one positive skin test and 20ppb for those with >one positive skin test).  FeNO was measured with a chemiluminescence analyser (Sievers NOA 
280i, Colorado, USA).  Inclusion criteria included age > four years, attending a hospital asthma clinic, having persistent asthma and being prescribed regular 
asthma preventer treatment.  Exclusion criteria included poor treatment adherence and not being able to take inhaled medication.  The following questions 
were scored 0 (no symptoms/normal activity) to 6 (greatest symptoms/disruption of activity): How often did you experience asthma symptoms? How much 
did your asthma symptoms bother you today? How much activity could you do today? How often did your asthma affect your usual activities today?  Being 
uncontrolled was defined as an increased in symptoms score of ≥15% since the previous visit.  The symptom score could only be identified for the baseline 
assessment but not for the three and six month visits.  Prescribing of oral corticosteroids for asthma attacks was at the discretion of the attending doctor. 
Pijnenburg et al 
4
 included 86 participants in the Netherlands and data were collected at baseline, three, six, nine and twelve months.  The intervention 
compared asthma treatment guided by symptoms versus symptoms plus FeNO (applying a cut off of 30 ppb).  Spirometry was not measured at the three 
and six month follow ups. FeNO was measured using the using the NIOX chemiluminescence analyzer (Aerocrine AB, Solna, Sweden).  Inclusion criteria were 
age 6-18 years, being atopic and having had no change to ICS dose for the three months prior to recruitment.  There were no exclusion criteria.  A daily 
symptom diary scored the following as 0 (none) to 3 (greatest symptoms): daytime dyspnoea, daytime wheezing, daytime cough, night time dyspnoea, 
night time wheezing, night time cough and being uncontrolled was defined as a mean of the symptoms score over two weeks of >14.   
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Pike et al 
5
 recruited 90 participants in the UK and collected data at baseline, two, four, six, eight, ten and twelve months. The two month data was used to 
represent three months, and if six month data were missing then the four month data were used.  The intervention compared asthma treatment guided by 
symptoms versus symptoms plus FeNO (applying a cut off of 25ppb).  FeNO was measured using the NIOX MINO device (Aerocrine AB, Solna, Sweden). 
Inclusion criteria were age 6-17 years, diagnosed asthma, attending one of three hospital asthma clinics and being prescribed ≥400 microg BUD.  Exclusion 
criteria were being unable to provide FeNO or FEV1 measurements, active smoking, poor treatment adherence, a history of a life-threatening asthma attack 
or requirement for maintenance oral corticosteroids.  Symptoms were scored none, trivial, mild, moderate or severe for the following outcomes: cough, 
wheeze, sputum production, shortness of breath while walking, waking due to night time cough, waking due to night time cough, waking due to night time 
sputum production and waking due to shortness of breath.  The blinded clinician categorised each participant’s asthma as well controlled (symptoms and 
reliever inhaler <1/week and FEV1 >90% predicted); controlled (symptoms or reliever inhaler use 1-2/week, or FEV1 >80% predicted), or poorly controlled 
(symptoms or reliever inhaler use >2/week, or FEV1 <80% predicted) (modified from Smith et al
6
). 
Szefler et al
7 
recruited 546 participants in the USA and collected information at baseline, 1.5, 3.2, 5, 7, 8.5 and 10.5 months. We utilised the baseline 
information, 3.2 month assessment to represent three months and the seven month assessment to represent six months. If data were missing at these time 
points, data from the 1.5 month assessment was used to represent three month assessment, and the five month assessment used to impute at six months.  
The intervention compared asthma treatment guided by symptoms plus FEV1 (applying a cut off of 80% predicted) versus symptoms, FEV1 and FeNO 
(applying cut offs of 20, 30 and 40 ppb).  FeNO was measured using a rapid-response chemiluminescent analyser (NIOX, Aerocrine AB, Sweden).  Inclusion 
criteria were age 12-20 years, living in a household where ≥20% of resident’s income was below the federal poverty threshold, physician diagnosed asthma 
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which required long-term treatment and was persistent and/or uncontrolled. Individuals with cotinine confirmed active smoking were excluded. Having 
uncontrolled asthma was defined as a score of <19 on the asthma control test
8
. 
Voorend-van Bergen et al
9
 undertook a study of 181 participants and collected data at baseline, 4, 8 and 12 months. We assigned the four and eight month 
data to represent three and six month assessments respectively.  Spirometry was only measured at baseline and twelve months.  The intervention 
compared asthma treatment guided by symptoms versus symptoms plus FeNO (applying cut offs of 20 and 50 ppb).  Participants in a third arm of this trial 
(a web-based intervention) were not included. FeNO was measured using a NIOX chemiluminescence analyzer or NIOX MINO (Aerocrine AB, Stockholm, 
Sweden).  Inclusion criteria were age 4-18 years, diagnosed asthma, sensitisation to inhaled allergen, bronchodilator response of 9%, attending one of 
seven hospital clinics in the Netherlands and being prescribed inhaled corticosteroids for more than three months.  Exclusion criteria included active 
smoking, admission to intensive care for asthma, inability to provide FeNO measurement and use of omalizumab. Having uncontrolled asthma was defined 
as a score of <19 on the asthma control test
8
. 
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Supplemental table 1. Details of FEV1 z scores and centile scores both for individual trials and all trials combined.  Raw data were not available for the trials 
by Peirsman et al or Pijnenburg et al. 
  
Fritsch
1
 Peirsman
2
 Petsky
3
 Pijnenburg
4
 Pike
5
 Szefler
7
 
Voorend-van 
Bergen
9
 
All populations 
combined 
Total number of participants 47 99 63 86 90 546 181 1112 
FEV1 z score Number of observations 47 - 54 - 90 546 157 894 
mean (SD) -0.61 (1.28) - -0.07 (1.41) - -0.51 (1.34) -0.58(1.66) -0.49 (1.09) -0.53 (1.51) 
FEV1 centile 
score 
Number of observations 47 - 54 - 90 546 157 894 
Median(IQR) 
28.1 (7.4, 
58.0) 
- 
48.2 (22.1, 
75.4) 
- 
27.2 (7.2, 
66.2) 
22.5 (4.01, 
71.9) 
31.3 (12.6, 
58.4) 
27.9 (5.9, 
66.9) 
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Supplemental table 2. Relationship between falling % FEV1/FVC or %FEF25-75 over a three month period and odds of asthma attack or loss of asthma control 
during the next three months.  Results are from a one stage individual patient data analysis.  All models adjusted for sex, age, treatment with long acting 
beta agonists at baseline, treatment with leukotriene receptor antagonist at baseline, asthma control at baseline, change in dose of inhaled corticosteroid 
between baseline and three months. †The model also includes asthma attack between baseline and 3 months.  The change in %FEV1/FVC or %FEF25-75 model 
included %FEV1/FVC or %FEF25-75 at baseline. *For change in %FEV1/FVC “per unit” means for each percentage change (e.g. from 98% to 97% FEV1/FVC).  
 
Measurement of respiratory function Asthma outcome Odds Ratio per unit* reduction in 
%FEV1/FVC, %FEF25-75 or FVC 
 
Change (baseline to 3m) in %FEV1/FVC 
≥1 asthma attack between baseline and three months 1.013(0.977, 1.050) p=0.492 n=526 (2 trials) 
Asthma uncontrolled at three months 1.026 (0.99, 1.061) p=0.166 n=544 (2 trials) 
 
Change (baseline to 3m) in %FEF25-75  
≥1 asthma attack between baseline and three months 1.009 (0.995, 1.024) p=0.200 n=480 (1 trial) 
Asthma uncontrolled at three months 1.006 (0.993, 1.020) p=0.353 n=498 (1 trial) 
 
Change (baseline to 3m) in %FVC  
≥1 asthma attack between baseline and three months 1.034 (1.034, 1.065) p=0.026 n=542 (3 trials) 
Asthma uncontrolled at three months 1.023 (0.994, 1.053) p=0.126 n=544 ( 2 trials) 
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Supplemental table 3. Relationship between baseline % FEV1 or baseline FeNO or change in %FEV1 or %change in FeNO and risk of asthma attack or loss of 
asthma control during the next three months.  Results are from a one stage individual patient data analysis and are stratified by trial arm.  
 
 Only children in standard treatment arm Only children in FeNO treatment arm 
Per unit fall in % FEV1 between 
baseline and three months 
≥1  asthma attack between three 
and six months 
1.026 (0.994, 1.058) p = 0.119 n = 366 1.014 (0.987, 1.043) p = 0.314 n = 359 
Asthma uncontrolled at six months 1.006 (0.981, 1.033) p = 0.632 n = 363 1.023 (0.999, 1.048) p = 0.061 n = 349 
Per % rise in FeNO between baseline 
and three months 
≥1  asthma attack between three 
and six months 
1.001 (0.998, 1.003) p=0.574 n=463  1.001 (0.998, 1.003) p=0.431 n=475 
Asthma uncontrolled at six months 1.001 (0.999, 1.004) p=0.173 n=456  1.000 (0.998, 1.003) p=0.633 n=462 
Per unit reduction %FEV1 at baseline Odds ratio for ≥1 asthma attack 
between baseline and three months 
0.999 (0.980, 1.019) p = 0.971 n=493  1.026 (1.005, 1.049) p = 0.017 n = 480 
Asthma uncontrolled at three 
months 
1.001 (0.989, 1.013) p = 0.846 n = 479 0.981 (0.967, 0.995) p = 0.008 n = 460 
Per ppb increase in FeNO at baseline 
 
Odds ratio for ≥1 asthma attack 
between baseline and three months 
1.002 (0.993, 1.012) p=0.650 n=476 1.001 (0.992, 1.010) p=0.771 n=490 
Asthma uncontrolled at three 
months 
1.002 (0.996, 1.008) p=0.591 n=460  0.996 (0.988, 1.003) p=0.296 n=469 
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Supplemental table 4.  Relationship between falling % FEV1 or rising %change in FeNO over a three month period and risk of asthma attack or loss of asthma 
control during the next three months where data from the cohorts
1, 2, 7
 where FEV1 was used to guide treatment were excluded.   
Change in measurement of 
respiratory function 
Asthma outcome Odds Ratio per unit change in FEV1 or FeNO 
Change (baseline to 3m) in % FEV1 Loss of control 0.973 (0.926, 1.021) p =0.266 
Asthma attack 1.029 (0.986, 1.074) p = 0.194 
% change in FeNO (baseline to 3m) Loss of control 0.999 (0.996, 1.002) p = 0.507 
Asthma attack 1.004 (1.000, 1.008) p = 0.029 
% FEV1 at baseline Loss of control 0.998 [0.988, 1.008] p = 0.737 
Asthma attack 1.001 [0.989, 1.013] p = 0.925 
FeNO at baseline Loss of control 0.989 [0.971, 1.008] p = 0.273 
Asthma attack 1.027 [0.999, 1.055] p = 0.054 
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Supplemental table 5.  Relationship between falling FEV1 z score or FEV1 centile over a three month period and the odds of an asthma attack or having poor 
asthma control during the next three months.  *For change in FEV1, “per unit” means for each percentage change (e.g. 1 z score decrease in FEV1 or a 
decrease of one FEV1 centile). 
 
Change in measurement of 
respiratory function 
Asthma outcome Odds Ratio per unit change in FEV1* 
 
Change (baseline to 3m) in 
FEV1 z score 
≥1  asthma attack between 
three and six months† 
1.417 (1.036, 1.939) p=0.029  
n=625 (4 trials) 
Asthma uncontrolled at six 
months 
1.394 (1.086, 1.790) p=0.009 
n=602 (3 trials) 
 
change in FEV1 centile 
(baseline to 3m) 
≥1  asthma attack between 
three and six months† 
1.011 (0.9996, 1.027) p=0.157 
n=625 (4 trials) 
Asthma uncontrolled at six 
months 
1.017 (1.005, 1.031) p=0.006 
n=602 (3 trials) 
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Supplemental table 6. Relationship between falling % FEV1 (standardised to NHANESIII) over a three month period and risk of asthma attack or loss of 
asthma control during the next three months.  Results are from a one stage individual patient data analysis.  All models adjusted for sex, age, treatment 
with long acting beta agonists at baseline, treatment with leukotriene receptor antagonist at baseline, control at baseline, change in dose of inhaled 
corticosteroid between baseline and three months 
Change in measurement of 
respiratory function 
Asthma outcome Odds Ratio per unit change in FEV1  
 
Change (baseline to 3m) in% 
FEV1 
≥1  asthma attack between three 
and six months 
1.025 (1.002, 1.047) p=0.031          
n=716 (5 trials) 
Asthma uncontrolled at six 
months 
0.981 (1.0, 0.993) p=0.055           
n=693  (4 trials) 
 
%FEV1 at baseline 
 
≥1 asthma attack between 
baseline and three months 
1.017(1.001, 1.034) p=0.039          
n=974 (7 trials) 
Asthma uncontrolled at three 
months 
1.012 (1.001, 1.021) p=0.033        
n=940 (6 trials) 
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Supplemental table 7. Relationship between baseline FEV1 z score and centile and odds of asthma attack or asthma being uncontrolled during the next 
three months.  Results are from a one stage individual patient data analysis.  All models adjusted for sex, age, treatment with long acting beta agonists at 
baseline, treatment with leukotriene receptor antagonist at baseline, asthma control at baseline and change in dose of inhaled corticosteroid between 
baseline and three months. *“Per unit” means for each z score or centile percentage reduction. 
Measurement of 
respiratory function 
Asthma outcome Odds Ratio per unit* reduction in 
FEV1  
 
 
FEV1 z score at baseline 
 
≥1 asthma attack between 
baseline and three months 
1.065 (0.87, 1.30), p = 0.537 
n=807 (5 trials) 
Asthma uncontrolled at three 
months 
0.945 (0.841, 1.062) p =0.344 
n=777 (4 trials) 
 
FEV1 centile at baseline 
 
≥1 asthma attack between 
baseline and three months 
1.002 (0.993, 1.011) p =0.669 
n=807 (5 trials) 
Asthma uncontrolled at three 
months 
0.999 (0.993, 1.004) p = 0.668 
n=777 (4 trials) 
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ABSTRACT (word count 249) 
Background. Repeated measurements of spirometry and fractional exhaled nitric oxide (FeNO) are 
recommended as part of the management of childhood asthma, but the evidence base for such 
recommendations is small.  We tested the hypothesis that reducing spirometric indices or increasing 
FeNO will predict poor future asthma outcomes.  
Methods.  A one-stage individual patient data meta-analysis used data from seven randomised 
controlled trials where FeNO was used to guide asthma treatment, and where spirometric indices 
were also measured.  Change in %FEV1 and % change in FeNO between baseline and three months 
were related to having poor asthma control and to having an asthma exacerbation between three 
and six months after baseline.   
Results. Data were available from 1112 children (mean age 12.6 years, mean %FEV1 94%). A 10% 
reduction in %FEV1 between baseline and three months was associated with 28% increased odds for 
asthma exacerbation [95% CI 3, 58] and with 21% increased odds for having poor asthma control 
[95% CI 1, 45] six months after baseline. A 50% increase in FeNO between baseline and three months 
was associated with 11% increase in odds for poor asthma control six months after baseline [95% CI 
0, 16]. Baseline FeNO and %FEV1 were not related to asthma outcomes at three months.   
Conclusions. Repeated measurements of %FEV1 which are typically within the “normal” range add to 
clinical risk assessment of future asthma outcomes in children. The role of repeated FeNO 
measurements is less certain since large changes were associated with small changes in outcome 
risk.  
Keywords: Asthma, Child, Monitoring, Nitric oxide, Spirometry 
 
  
Page 38 of 57
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL
4 
 
ABBREVIATION LIST 
BUD Budesonide 
ERS European Respiratory Society 
FeNO Fractional Exhaled Nitric Oxide 
FEF25-75 Forced Expiratory Flow at 25-75% of FVC 
FEV1 Forced Expiratory Volume in one second 
FVC Forced Vital Capacity 
GLI Global Lung Initiative 
ICS Inhaled corticosteroid 
IPD Individual Patient Data Analysis 
IQR Inter-quartile range 
LABA Long Acting Beta Agonist 
LTRA Leukotriene Receptor Antagonist 
NHANES National Health and Nutrition Examination Survey 
OR Odds ratio 
ppb Parts per billion 
RCT Randomised Controlled Trial 
SD Standard deviation 
UK United Kingdom 
USA United States of America 
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INTRODUCTION 
Asthma is a common condition affecting 1 million children in the UK
1
 and 6 million in the USA
2
.  
Guidelines recommend that objective markers of respiratory function (e.g. forced Expiratory Volume 
in one second (FEV1)) and airway inflammation (e.g. fractional exhaled nitric oxide, FeNO) may be 
used in conjunction with symptoms to guide asthma preventive treatment in children.  However 
these recommendations differ between guidelines, and none gives clinicians advice how to interpret 
changes in spirometry when values fall within the normal range, yet FEV1 (the most commonly used 
spirometric index) is usually within normal limits 
3
.   
One guideline recommends that lung function should be “monitored and recorded” only in children 
aged over 12 years
4
.  Two guidelines recommend that FEV1 may be useful for monitoring of asthma 
for children aged over five to seven years
5, 6
. A fourth guideline
7
 recommends that lung function 
should be measured three-to-six months after treatment is started and “periodically” thereafter, and 
that %FEV1 less than 60% identifies a patient at risk for future asthma exacerbations.  A fifth 
guideline
8
 recommends that lung function should be measured every one to two years (more 
frequently when symptoms are poorly controlled) and suggests that treatment might be stepped up 
if %FEV1 is below 80% or 60%.  Some guidelines suggest that a 20% drop in FEV1 relative to personal 
best identifies an individual at risk for future asthma exacerbations
5, 7
.  
Although FeNO is recommended by the US Food and Drug Administration for monitoring asthma
9
 
there is no consensus on how results should be interpreted; one international guidelines states that 
a change in FeNO of 10 parts per billion or 20% may be clinically relevant
10
.   
To understand the relationship between change in spirometry and FeNO and asthma outcomes we 
obtained individual patient data (IPD) from seven FeNO randomised controlled  trials (RCTs) where 
details of spirometry, FeNO, asthma control and the occurrence of asthma exacerbations were 
collected longitudinally 
11-17
.  Our primary hypothesis was that falling spirometric indices (with %FEV1 
as the primary index) and/or rising FeNO between randomisation and three months follow up will be 
Page 40 of 57
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL
6 
 
associated with increased risk for asthma being uncontrolled and for an asthma exacerbation 
between three and six months follow up.  The secondary hypothesis was that at baseline, low 
spirometric indices and high FeNO will be associated with increased risk for asthma being 
uncontrolled and for an asthma exacerbation between baseline and three months follow up. 
 
METHODS 
Study design   
Authors of published RCTs where measurements of FeNO was used to guide asthma treatment in 
children
18
 were invited to provide anonymised data for IPD
19
. The outcomes were asthma 
exacerbation (defined as a prescription of prednisolone during the follow-up period and derived 
using data provided by study authors) and poor asthma control (defined by per trial protocol by 
symptom score, and including FEV1 cut off values in some trials
11, 12, 16
 but not including an asthma 
exacerbation).  The supplement provides definitions of being uncontrolled.  For all RCTs, prescribing 
of oral corticosteroids for asthma exacerbations was at the discretion of the attending doctor.  The 
explanatory variables between baseline and three months follow up were absolute change and 
%change in FeNO and absolute change in percentage of predicted (%) spirometry; the analysis of 
change in % spirometry and % change in FeNO included the corresponding baseline measurement.  
The relationship between outcomes and the following explanatory variables at baseline were 
sought: FeNO and %FEV1, %FEV1/FVC, %FEF25-75 and %FVC.  Figure one shows which physiological 
measurements (and changes) were linked to later asthma outcomes in this study.  Additional 
covariates collected at baseline and included in the models were: age, gender, height, weight, 
ethnicity, trial arm, dose of inhaled corticosteroid (ICS, as daily budesonide equivalent dose, BUD), 
prescribed long acting beta agonist (LABA) or not, prescribed leukotriene receptor agonist (LTRA) or 
not, asthma control and treatment compliance. For each follow up visit, the following variables were 
collected: FeNO, FEV1, height, dose of ICS, asthma control and asthma exacerbation since the 
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previous visit.  The focus of this study was follow up at three and six months since these are typically 
used in asthma clinics; for trials where there was no three or six month assessment, the assessment 
closest to these time points was used.  In all but two studies
14, 15
, absolute spirometry data were 
available and expressed as percentage of predicted to the Global Lung Initiative standard
20
; where 
absolute data were not available, the % predicted value provided by the local team was used for 
analysis. Whilst %FEV1 was the primary spirometric index of interest, %FEV1/FVC, %FEF25-75 and %FVC 
were also considered to determine which index had the greatest precision for future outcomes.  For 
completeness, FEV1 was also expressed as a Z scores and centile (standardised to the Global Lung 
Initiative standard
20
).  Additionally, as a sensitivity analysis, %FEV1 was derived using National 
Asthma Education and Prevention Program (NHANES) III standard
21
 to determine whether any 
relationship between %FEV1 and later outcome was dependent on the standard used.   Body Mass 
Index (BMI) was derived and International Obesity Task Force weight categories created
22
. In each 
trial, FeNO was measured in accordance with the 2005 guideline
23
.  Ethical approval was obtained 
for each individual study but was not required for the IPD. 
 
Individual patient data analysis 
Demographic and baseline characteristics were obtained for each study. A one-stage IPD meta-
analysis was undertaken using the melogit command in STATA with study included as a random 
effect. All models were adjusted for the baseline variables of age, gender, LABA, LTRA, asthma 
control, ICS dose, arm of trial and where relevant baseline FeNO or baseline FEV1. A one-stage 
approach was used rather than a two-stage as some of the studies had low event counts (few 
asthma exacerbations) and adoption of one-stage in this instance is recommended by Burke et al
24
. 
Sensitivity analyses considered separately outcomes for individuals in FeNO intervention and 
standard care arms of the trials, and also excluding data from trials where %FEV1 was used to guide 
treatment decisions 
11, 12, 16
. STATA version 14 was used for analysis. 
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RESULTS 
Study subjects 
Data from seven paediatric RCT were analysed 
11-17
, data from an eighth RCT could not be obtained 
25
.  Details of population inclusion and exclusion criteria are presented in the supplement. The IPD 
included data on 1112 participants. In two studies
14, 17
 spirometry was only measured at baseline and 
at 12 months and change in %FEV1 between baseline and three months could not be calculated.  
There was a predominance of male participants (58%) and mean (standard deviation(SD)) age was 
12.6 (3.1) years, table 2.  Median values of FeNO varied between 18 and 34 parts per billion (ppb) 
with an overall median (interquartile range (IQR)) of 22ppb (12, 43). Mean %FEV1 values at baseline 
varied between 89% and 98% predicted with an overall mean (SD) of 94% (18).  Details of mean FEV1 
z scores and centile are presented in supplemental table 1. The Pearson correlation coefficient 
between FeNO and %FEV1 at baseline was -0.184 (n=1025, p <0.001) and between % change in FeNO 
(baseline to 3 months) and change in %FEV1 (baseline to 3 months) was -0.127 (n=759, p <0.001). 
Overall 7% of participants had an asthma exacerbation during the first 3 months and 12% in the 
second three months, while 27% were uncontrolled at baseline, 25% at 3 months, and 23% at six 
months, table 3.  An asthma exacerbation occurred between baseline and three months in 47 (7%) 
of the 718 participants with controlled symptoms at baseline and in 27 (12%) of 230 with 
uncontrolled symptoms at baseline.  
 
Relationship between change in spirometry and percentage change in FeNO between baseline and 
three months and outcomes between three and six months 
Between baseline and 3 months, the mean (SD) change in %FEV1 was -0.17 (10.4), the median 
absolute change in FeNO was 0.6 ppb (IQR -7.9, 12.2) and the median % change in FeNO 
(interquartile range) was 3.7% (IQR -30.4, 66.7).  A fall in % FEV1 was related to increased odds of an 
asthma exacerbation over the following three months (e.g. a reduction of 10% FEV1 between 
baseline and three months was associated with increased odds ratio (OR) for future exacerbation 
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between three and six months of 1.3 [1.0, 1.6], p=0.027) and loss of future asthma control (e.g. a 
reduction of 10% FEV1 was associated with increased odds ratio for uncontrolled asthma 1.2 [96% CI 
1.0, 1.5], p=0.046), table 4.  A reduction of 10% FVC was also associated with increased odds for a 
future exacerbation (OR 1.40 [1.04, 1.88], p=0.026), supplemental table 2.  A 50% increase in FeNO 
between baseline and three months was associated with 11% increased odds of asthma being 
uncontrolled at six months [95% 0, 16] (p=0.014) but not odds of an exacerbation between three 
and six months, table 4. When both change in %FEV1 and %change in FeNO were considered in the 
same model, the odds ratio for asthma being uncontrolled remained significant for FeNO (p=0.036) 
but not for %FEV1 (p=0.061).  Neither change in %FEV1/FVC or %FEF25-75 (supplemental table 2) nor 
absolute change in FeNO (table 4) were associated with outcomes. The associations between change 
in %FEV1 and % change in FeNO did not achieve significance when each trial arm was considered 
separately (supplemental table 3).  When the RCTs where %FEV1 was used to guide treatment were 
excluded there was an association between rising FeNO and future asthma exacerbation (p=0.029) 
but associations between change in FEV1 and outcomes were not significant, supplemental table 4.  
Among the subset of RCT where FEV1 z score and centile values could be derived, falling z scores 
were associated with increased odds for both asthma exacerbations and being uncontrolled and 
falling centile score with being uncontrolled, supplemental table 5. The results seen with change in 
% FEV1 using the Global Lung Initiative (GLI) standard were also seen when the NHANES III standard 
was used, supplemental table 6.   
 
Relationship between baseline FeNO and spirometric indices and outcomes at three months 
Percentage of predicted FEV1/FVC at baseline (but no other spirometric index) was related to the 
odds of asthma exacerbation at three months during this interval (p=0.016), table 5.  No index of 
spirometry at baseline was related to having uncontrolled asthma at three months.  FeNO at 
baseline was not related to asthma outcomes at three months (table 5).  Supplementary table 6 
demonstrates that when FEV1 was standardised to the NHANES III data, reducing %FEV1 at baseline 
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was associated with increased odds for future asthma exacerbation (p=0.033) and a trend for 
reduced odds for asthma not being controlled in future (p=0.055).  Baseline FEV1 z score or centile 
were not related to outcomes (supplemental table 7). 
 
DISCUSSION 
This study sought to understand the relationship between changes in spirometric measurements and 
FeNO and future asthma outcomes.  The first finding was that, independent of all factors which 
might influence treatment decisions, falling %FEV1 (even within the range of 80-120% commonly 
considered as “normal”) was associated with increased odds for future asthma exacerbation and 
having uncontrolled asthma.  A second finding was that an absolute change in FeNO (table 4) did not 
predict outcomes, and only a large rise in % change in FeNO was related to a small increase in the 
odds for having uncontrolled asthma in future.  We also observed that at baseline, a “one off” 
%FEV1/FVC ratio (but not %FEV1) was associated with future odds for asthma exacerbation.  
Together the results suggest that change in %FEV1 can be used as part of risk assessment for asthma 
outcomes.  The role of change in FeNO is less clear and future clinical trials could include % change in 
FeNO as part of a treatment algorithm for children with asthma. 
The individuals whose data contributed to this study were participating in RCTs, and this could mean 
that the results are not necessarily generalisable for at least two reasons.  First, participants in RCTs 
often have to fulfil specific eligibility criteria, receive more clinical contact than standard care and 
often have better outcomes such as fewer asthma exacerbations, but these differences are likely to 
weaken any association between FeNO or %FEV1 and asthma outcomes by narrowing the phenotype 
of participants and improving outcomes.  Secondly, the participants in our study had treatment 
guided by FeNO (and %FEV1 in three studies) and thus the predictive variables in our study may have 
affected the outcome (e.g. rising FeNO leading to increased ICS resulting in good asthma control).  
We justify inclusion of data from these trials because firstly FeNO and, in all but one study
14
, %FEV1 
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did not differ between trial arms and secondly, if FeNO or %FEV1 did improve asthma outcomes by 
protocol-driven treatment changes this would have weakened any association between FeNO or 
%FEV1 and asthma control or asthma exacerbations.  Our inclusion of participants in RCTs may 
therefore have weakened the associations described, and in “real life” change in %FEV1 and % 
change in FeNO may have greater precision for outcomes than indicated by our results.  
There are some limitations to our study.  First, the methodologies of the RCTs were different and in 
particular in three of the RCTs
15-17
 the intervals between assessments did not include multiples of 
three months, and this heterogeneity may have weakened the associations described, assuming that 
the relationship between FeNO and FEV1 and outcomes changes over time. Different methods were 
used to assess asthma control; again this would weaken and not strengthen the associations 
described between baseline %FEV1 or %change in FeNO and being uncontrolled in future.  A 
secondfurther limitation is that the range of %FEV1 values was relatively narrow and the incidence of 
asthma exacerbations was relatively low and this could make the relationship between physiological 
measurement and clinical outcome difficult to detect, but nonetheless we were still able to observe 
an association between %FEV1 and future asthma exacerbations.  A thirdfinal limitation is that we 
did not have an objective measure of adherence and could not consider how non-adherence may 
have influenced asthma control and exacerbations, however this information is not available for 
most clinicians and thus our study reflects “real world”.  A fourth limitation is that none of the RCTs 
included an assessment of short-term variability of pulmonary function, such as peak expiratory flow 
variability or bronchodilator response, and we are not able to say how short-term variability in 
pulmonary function might be related to future asthma outcomes. 
The magnitude of the change in odds ratio for an asthma exacerbation or being uncontrolled in 
future in the context of changing %FEV1 and FeNO were relatively small, and this is partly due to our 
including RCT participants as previously discussed and partly due to the fact that the model 
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considered many other factors which might predict poor asthma outcomes, e.g. current symptom 
control, treatment level, current %FEV1.  
In our sensitivity analyses we excluded the three studies where %FEV1 was used to guide treatment 
and the results seen in the whole population were no longer significant and this is most likely 
explained by lack of power. We when split results by trial arm, and the significant associations seen 
between change in %FEV1 and %change in FeNO for the whole population were also non-significant 
and this is also most likely due to lack of power in the analysis.   
We are not aware of published studies which relate change in spirometry to future asthma 
outcomes, but there are several studies where spirometry on a single occasion has been related to 
subsequent asthma outcomes in children.  One study reported an inverse relationship between 
reduced %FEV1 and increased risk for asthma exacerbation in the next 12 months
26
.  Two further 
studies
27, 28
 (data from one
27
 contributed to the present IPD) reported that reduced FEV1/FVC ratio 
was associated with increased risk for future exacerbation.   
The 2015 European Respiratory Society (ERS) Task Force on Monitoring Asthma in Children
29
 stated 
that “the meaning of significant changes in FeNO in a longitudinal setting is still unclear and needs 
further attention, and that “the use of ‘personal best’ cut-off points in FeNO algorithms requires 
further investigation”.  Our study findings suggest that a % relatively large rise (50%) in FeNO over 
three months (independent of treatment and initial symptoms) may be a useful predictor of having 
uncontrolled asthma in future but not for asthma exacerbations. Additionally, our results suggest 
that a single FeNO value and absolute change in FeNO over time are unlikely to be clinically useful. 
In summary our results suggest that %FEV1 within the “normal” range over three month periods 
could assist with risk assessment in childhood asthma and these findings now need replicating 
elsewhere.  A fall in %FEV1 and a rise in FeNO should prompt an evaluation of medication adherence, 
inhaler technique, perception of symptoms and exposure to either allergens or viral infection. The 
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relationship between changes in FeNO measurements and asthma outcomes is less clear and 
requires further evaluation.  
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FIGURE LEGEND 
Figure one.  A diagram showing how different physiological measurements were linked to later 
asthma outcomes in the study’s analyses. The analyses used data collected at recruitment to seven 
clinical trials and at follow up assessments three and six months after recruitment.*Although % FEV1 
was the primary spirometric index, the following were also considered: %FEV1/FVC, %FEF25-75 and 
%FVC.  
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Table 1.  Details of the randomised controlled trials included in this individual patient data analysis 
 Mean age, y  
 
Intervals at follow up 
after baseline when 
FeNO was measured 
(months). Zero 
corresponds to baseline. 
Intervals at follow up after 
baseline when spirometry 
was measured (months).  
Zero corresponds to 
baseline  
Were 
absolute 
spirometry 
data 
available? 
Which 
spirometric 
indices were 
available? 
Was 
there a 
run in 
period? 
Was 
atopy an 
inclusion 
criteria?  
What measure of asthma 
control was used? 
FeNO 
arm 
Control 
arm 
Fritsch
11
 11.3 12.1 0, 1.5, 3, 4.5, 6 0, 1.5, 3, 4.5, 6 Yes FEV1, FVC Yes Yes Unvalidated symptom diary 
Peirsman
12
 10.6 10.7 0, 3, 6, 9, 12 0, 3, 6, 9, 12 Yes FEV1 No Yes First four (of seven) questions 
on CACT*† 
Petsky
13
 9.9 10.1 0, 1, 2, 3, 4, 6, 8, 10, 12 0, 1, 2, 3, 4, 6, 8, 10, 12 Yes FEV1, FEF25-75, 
FVC 
Yes No Validated symptom diary 
Pijnenburg
14
 11.9 12.6 0, 3, 6, 9, 12 0, 12 No FEV1, FEF50, 
FVC 
Yes Yes Validated symptom diary 
Pike
15
 10.5 11.4 0, 2, 4, 6, 7, 10, 12 0, 2, 4, 6, 7, 10, 12 No FEV1, FVC No No Modified validated symptom 
diary† 
Szefler
16
 14.4 14.4 0, 1.5, 3.2, 5, 7, 8.5, 10.5 0, 1.5, 3.2, 5, 7, 8.5, 10.5 Yes FEV1, FEF25-75, 
FVC 
Yes No ACT*‡ plus FEV1 
Voorend-van 
Bergen
17
 
10.3 10.2 0, 4, 8, 12 0, 12 Yes FEV1, FEF75, 
FVC 
Yes Yes ACT and C-ACT* 
 
*ACT = asthma control test, C-ACT=Childhood Asthma Control Test 
†reliever medication use and FEV1 or ¶FEV1 alone were used in the treatment algorithm for both arms of the RCT but were not used to define being 
uncontrolled in the present study 
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Table 2. Characteristic of study participants at the baseline visit in each study 
  
Fritsch
11
 Peirsman
12
 Petsky
13
 Pijnenburg
14
 Pike
15
 Szefler
16
 
Voorend-van 
Bergen
17
 
All populations 
combined 
Total number of participants 47 99 63 86 90 546 181 1112 
%(number) male 60% (28) 67% (66) 49% (31) 65% (56) 57% (51) 53% (288) 68% (123) 58% (643) 
Age mean (SD) 11.5(3.1) 10.7 (2.1) 10.0 (3.2) 12.3 (2.8) 10.9 (2.6) 14.4 (2.1) 10.2 (3.0) 12.6 (3.1) 
range 6 to 17 5 to 14 4 to 16 6 to 18 5 to 16 12 to 19 4 to 18 4 to 19 
Trial arm Standard 25 50 32 46 46 270 92 561 
FeNO 22 49 31 40 44 276 89 551 
FeNO Number of observations 46 49 61 86 90 546 179 1057 
Median (ppb) 33.9 31.3 25.6 32 25.5 20.1 18.2 21.9  
IQR (ppb) (18.6, 58.6) (14, 69) (12.2, 47.5) (16.6, 52.5) (10, 48) (11.2, 40.6) (10.2, 30.4) (11.6, 43.0) 
% predicted 
FEV1 
Number of observations 47 98 54 86 90 546 157 1078 
mean (SD) 93.5 (15.7) 91.4 (15.7) 90.7 (15.6) 97.5 (17.5) 89.2 (14.3) 90.9 (16.6) 93.8 (13.0) 93.5 (18.1) 
% predicted 
FEV1/FVC 
Number of observations 47 0 0 0 0 546 156 749 
mean (SD) 90.1 (10.6) - - - - 91.3 (9.9) 93.4 (9.4) 91.7 (9.9) 
% with positive skin prick test  
100% 100% 
38% 
(24/63) 
100% 
76%       
(68/90) 
88%  
(467/531) 
100% 
89%  
(972/1097) 
Mean Centile 
BMI (SD) 
Number of observations 47 99 58 86 89 546 181 1106 
mean (SD) 67.6 (27.0) 52.1 (30.1) 48.5 (32.4) 60.8  (27.3) 64.2 (32.2) 83.1 (23.5) 58.9 (29.9) 70.7 (29.8) 
 
Obese 
Number of observations 47 99 58 85 89 526 181 1085 
% (number) overweight 28% (13) 12% (12) 16% (9) 14% (12) 25% (22) 28% (145) 20% (36) 23% (249) 
% (number) obese 8% (4) 1% (1) 2% (1) 4% (4) 8% (7) 31% (165) 3% (5) 17% (187) 
LTRA 
treatment 
prescribed 
Number of observations 47 99 58 86 90 546 181 1107 
% (number) yes  28% (13) 60% (59) 10% (6) 0 51% (46) 15% (80) 13% (23) 
21% (227) 
LABA Number of observations 47 99 58 86 90 546 181 1107 
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treatment 
prescribed 
% (number) yes  38% (18) 32% (32) 67% (39) 38% (33) 76% (68) 66% (360) 46% (84) 
57% (634) 
Median dose of inhaled corticosteroids 
(IQR)  
400 (0, 800) 320 (200, 400) 
400 (250, 
500) 
800 (400, 
1000) 
800 (400, 
1000) 
1000 (400, 
2000) 
400 (400, 
800) 
400 (400, 
1000) 
 
Ethnic group 
Number of observations 0 84 20 0 90 526 179  889 
White  82% (69)   92% (83) 
 
89% (160) 35% (312) 
Hispanic      65% (340) 
 
38% (340) 
 Other  18% (15) 100% (20)  8% (7) 35% (186) 11% (19) 28% (247) 
Asthma 
control 
status 
Number of observations 47 65 57 77 90 528 181 1045 
Asthma controlled 49% (23) 75% (49) 72% (41) 57% (44) 68% (62) 80% (421) 67% (122) 73% (762) 
Asthma not Controlled 51% (24) 25% (16) 28% (16) 43% (33) 31% (28) 20% (107) 33% (59) 27% (283) 
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Table 3.  Frequency of outcomes between baseline and three months and between three and six months post baseline.   
 
 
 
 
 
 
 
 
 
 
  
 
Exacerbation between 
baseline and three 
months 
Exacerbation 
between three 
and six months 
Asthma not 
controlled at 
three months 
Asthma not 
controlled at 
six months 
  % (n) % (n) % (n) n (%) 
Fritsch
11
 2% (1/47) 6% (3/47) 54% (25/46) 53% (25/47) 
Peirsman
12
 4% (4/99) 0% 25% (21/83) 21% (18/86) 
Petsky
13
 5% (3/63) 8% (5/63) not available not available 
Pijnenburg
14
 9% (8/86) 8% (7/86) 40% (32/81) 40% (31/78) 
Pike
15
 17% (15/90) 30% (27/90) 26% (23/90) 32% (29/90) 
Szefler
16
 7% (35/522) 15% (78/505) 21% (111/541) 17% (86/513) 
Voorend-van Bergen
17
 7% (12/181) 7% (12/181) 21% (38/179) 20% (36/178) 
Overall 7% (78/1088) 12% (132/1071) 25% (250/1010) 23% (225/992) 
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Table 4.  Relationship between falling % FEV1 or rising %change in FeNO over a three month period and odds of having an asthma attack or uncontrolled 
asthma during the next three months.  Results are from a one stage individual patient data analysis.  All models adjusted for sex, age, treatment with long 
acting beta agonists at baseline, treatment with leukotriene receptor antagonist at baseline, asthma control at baseline, change in dose of inhaled 
corticosteroid between baseline and three months. *For change in %FEV1, “per unit” means for each percentage change (e.g. from 98% to 97% FEV1) and 
for %change in FeNO means for each percent change (e.g. from 100 to 101ppb) and absolute change in FeNO “per unit” means per part per billion change 
(e.g. from 35 to 36ppb).  †Odds ra]o for outcomes were derived from the odds ra]o per unit change, for example odds ra]o for asthma attack after a 
reduction in %FEV1 of 5 is 1.025 to the power of 5.   ‡The model also includes asthma attack between baseline and 3 months.  The change in FeNO model 
included FeNO at baseline and the change in FEV1 model included FEV1 at baseline. 
Change in 
measurement of 
respiratory 
function 
Asthma outcome Odds Ratio per 
unit change in 
FEV1 or FeNO* 
Odds Ratio per 5, 10 and 20 reduction in %FEV1† Odds Ratio per 20 and 50% 
increase in FeNO† 
Odds Ratio per 20 and 50ppb 
increase in FeNO† 
%FEV1 
reduced by 5  
%FEV1 
reduced by 10 
%FEV1 reduced 
by 20 
20% increase 
in FeNO 
50% increase 
in FeNO 
20ppb increase 
in FeNO 
50ppb 
increase in 
FeNO 
 
Change (baseline 
to 3m) in% FEV1 
≥1  asthma attack 
between three 
and six months‡ 
1.025 (1.003, 
1.047) p=0.027 
n=716 (5 trials) 
1.131 
[1.015, 1.258] 
1.280          
[1.030, 1.583] 
1.639          
[1.062, 2.506] 
  
Asthma 
uncontrolled at 
six months 
1.019 (1.000, 
1.038) p=0.046 
n=693  (4 trials) 
1.099 
[1.000, 1.205] 
1.207        
[1.000, 1.452] 
1.457        
[1.000, 2.108] 
 
% change in 
FeNO (baseline 
to 3m) 
≥1  asthma attack 
between three 
and six months‡ 
1.001 (0.999, 
1.003) p=0.228 
n=929 (7 trials) 
 1.020           
[0.980, 1.062] 
1.051         
[0.951, 1.162] 
Asthma 
uncontrolled at 
six months 
1.002 (1.000, 
1.003) p=0.014 
n=897 (6 trials) 
1.041           
[1.000, 1.062] 
1.105         
[1.00, 1.162] 
 
Absolute change 
in FeNO 
(baseline to 3m), 
ppb 
≥1  asthma attack 
between three 
and six months‡ 
1.004 (0.998, 
1.010) p=0.197 
n=929 (7 trials) 
 1.083        
[0.961, 1.220] 
1.221            
[0.905, 
1.645] 
Asthma 
uncontrolled at 
six months 
1.002 (0.997, 
1.008) p=0.407 
n=897 (6 trials) 
1.041          
[0.942, 1.173] 
1.105         
[0.861, 
1.489] 
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Table 5.  Relationship between baseline % FEV1 or baseline FeNO and odds of asthma attack or 
asthma being uncontrolled during the next three months.  Results are from a one stage individual 
patient data analysis.  All models adjusted for sex, age, treatment with long acting beta agonists at 
baseline, treatment with leukotriene receptor antagonist at baseline, asthma control at baseline and 
change in dose of inhaled corticosteroid between baseline and three months. *For %FEV1, “per unit” 
means for each percentage reduction (e.g. from 98% to 97% FEV1) and for FeNO “per unit” means 
per part per billion change (e.g. from 35 to 36ppb). 
 
Measurement of 
respiratory function 
Asthma outcome Odds Ratio per unit* reduction in 
FEV1 or rise in FeNO 
 
 
%FEV1 at baseline 
 
≥1 asthma attack between 
baseline and three months 
1.011(0.997, 1.026) p=0.118 
n=973 (7 trials) 
Asthma uncontrolled at three 
months 
0.993 (0.984, 1.001) p=0.098 
n=939 (6 trials) 
 
%FEV1/FVC at baseline 
 
≥1 asthma attack between 
baseline and three months 
1.037 (1.007, 1.067) p=0.016 
n=706 (3 trials) 
Asthma uncontrolled at three 
months 
0.993 (0.973, 1.012) p=0.451 
n=715 (3 trials) 
 
 
FeNO (ppb) at baseline 
≥1 asthma attack between 
baseline and three months 
1.001 (0.995, 1.008) p=0.682 
n=966 (7 trials) 
Asthma uncontrolled at three 
months 
1.002 (0.997, 1.007) p=0.476 
n=929 (6 trials) 
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